Prognostic significance of serum prolactin levels in advanced breast cancer

Mitch Dowsett, Gail McGarrick, Adrian L. Harris, R. Charles Coombes, I. E. Smith, S.L. Jeffcoate
In: British Journal of Cancer · 1983 · vol. 47(6) , pp. 763–769 · doi:10.1038/bjc.1983.129 · PMID:6860546 · W2037045892
article OA: bronze CC0
📄 Open PDF View on OpenAlex View on PubMed View at publisher

Abstract

Serum prolactin concentrations were measured in 135 postmenopausal patients with advanced breast cancer prior to their treatment with one of 3 endocrine therapies: aminoglutethimide (AG), tamoxifen (T) + AG, or T + AG + danazol. The mean level of prolactin was higher, and there were more individuals with levels of prolactin greater than or equal to 500 mIUl-1, in the group of patients who did not respond to treatment. Of the patients whose disease progressed, those with prolactin levels greater than or equal to 500 mIUl-1 had a significantly shorter survival. It appears that high prolactin levels indicate a poor prognosis to endocrine therapy and the probability of a shorter than average survival time.

My notes (saved in your browser only)

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (22)

Source provenance

openalex
last seen: 2026-05-10T10:45:29.646959+00:00
License: CC0 · commercial use OK